EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study

Fengyu Wen, Jinwei Wang, Chao Yang, Fulin Wang, Yan Li, Luxia Zhang, José A Pagán

The Lancet Regional Health - Western Pacific · 2025-03 · 56 · 101493

DOI: 10.1016/j.lanwpc.2025.101493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Regional Health - Western Pacific, 2025-03. Verfasst von Fengyu Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Technology, Peking University Health Science Center, Beijing, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, China Academy of Space Technology, Chinese Academy of Meteorological Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the majority of patients with chronic kidney disease (CKD) live in low- and middle-income countries, most evidence on screening strategies is derived from high-income countries, where the contexts differ significantly. This study aims to assess the cost-effectiveness of population-based CKD screening strategies in both the general population and adults with diabetes in China.

Methods

A validated microsimulation model of CKD was developed to evaluate the costs and health consequences of population-based CKD screening strategies from a societal perspective. A cohort of the population aged 45 years in China was simulated over their lifetime. Model parameters were estimated based on the existing literature and various data sources in China. Main outcomes included the averted number of cases with cardiovascular disease (CVD) and kidney failure with replacement therapy (KFRT) under the population-based screening strategy compared with usual care, and the incremental cost-effectiveness ratios (ICERs). CKD screening with different frequencies and for different age groups in both the general population and adults with diabetes were considered. One-way sensitivity analyses were performed to assess the robustness of the results.

Findings

The ICER of annual screening starting at 45 years of age was $10,588 per quality-adjusted life year (QALY) for the general population and $9184 per QALY for adults with diabetes. Other screening strategies were also cost-effective compared to usual care, with ICERs less than three times the per-capita gross domestic product of China ($35,501). The most prominent absolute decrease in lifetime incidence of KFRT and CVD were also observed with the annual screening strategy in both the general population and in adults with diabetes. Specifically, the decreases were 1.88 and 8.55 per 1000 individuals for KFRT, and 35.07 and 19.92 per 1000 individuals for CVD, respectively.

Interpretation

CKD screening in both the general population and adults with diabetes is cost-effective and could avert substantial numbers of KFRT and CVD cases in China. Funding: This study was supported by grants from National Natural Science Foundation of China (72125009), National Key Research and Development Program of China (2022YFF1203001), National High Level Hospital Clinical Research Funding (State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, 24QZ007), Peking University Medicine Sailing Program for Young Scholars' Scientific & Technological Innovation (BMU2023YFJHMX014), Young Elite Scientists Sponsorship Program by CAST (2022QNRC001), and CAMS Innovation Fund for Medical Sciences (2019-I2M-5-046).

Schlagwörter

Stichwörter der Autor:innen

CKD screeningCost-effectiveness analysis

Autor:innen und Institutionen

  • Institute of Medical Technology, Peking University Health Science Center, Beijing, China.
  • National Institute of Health Data Science at Peking University, Beijing, China.
  • Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
  • Peking University Institute of Nephrology, Beijing, China.
  • Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
  • State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.

Förderung

  • NIDDK NIH HHS
  • China Academy of Space Technology
  • Chinese Academy of Meteorological Sciences
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Peking University

Zitieren

APA

Wen, F., Wang, J., Yang, C., Wang, F., Li, Y., Zhang, L., & Pagán, J. A. (2025). Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study. The Lancet Regional Health - Western Pacific, 56, 101493. https://doi.org/10.1016/j.lanwpc.2025.101493

Vancouver

Wen F, Wang J, Yang C, Wang F, Li Y, Zhang L, et al. Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study. The Lancet Regional Health - Western Pacific. 2025;56:101493. doi:10.1016/j.lanwpc.2025.101493

BibTeX
@article{Wen2025,
  author = {Wen, Fengyu and Wang, Jinwei and Yang, Chao and Wang, Fulin and Li, Yan and Zhang, Luxia and Pagán, José A},
  title = {Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study},
  journal = {The Lancet Regional Health - Western Pacific},
  year = {2025},
  volume = {56},
  pages = {101493},
  doi = {10.1016/j.lanwpc.2025.101493}
}
Kostenlos starten →